What is HC Wainwright’s Forecast for ACTU Q1 Earnings?

Actuate Therapeutics, Inc. (NASDAQ:ACTU) – Research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Actuate Therapeutics in a note issued to investors on Monday, August 18th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of ($0.25) per share for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. HC Wainwright also issued estimates for Actuate Therapeutics’ Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.27) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at ($0.99) EPS and FY2029 earnings at $0.21 EPS.

Separately, Craig Hallum began coverage on shares of Actuate Therapeutics in a report on Tuesday, April 22nd. They issued a “buy” rating and a $21.00 price target for the company. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $20.50.

Actuate Therapeutics Stock Down 3.4%

ACTU opened at $7.97 on Tuesday. Actuate Therapeutics has a 52 week low of $5.47 and a 52 week high of $11.99. The company has a fifty day moving average price of $7.10 and a two-hundred day moving average price of $7.96.

Actuate Therapeutics (NASDAQ:ACTU) last released its earnings results on Thursday, August 14th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.11).

Institutional Investors Weigh In On Actuate Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. BIOS Capital Management LP bought a new stake in Actuate Therapeutics in the 4th quarter valued at $78,753,000. Envestnet Asset Management Inc. bought a new stake in Actuate Therapeutics in the 4th quarter valued at $83,000. Mercer Global Advisors Inc. ADV bought a new stake in Actuate Therapeutics in the 4th quarter valued at $130,000. Voss Capital LP bought a new stake in Actuate Therapeutics in the 4th quarter valued at $440,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in Actuate Therapeutics in the 4th quarter valued at $84,000.

Insider Activity

In related news, Director Leslie W. Kreis acquired 71,428 shares of the business’s stock in a transaction that occurred on Friday, June 27th. The shares were acquired at an average cost of $7.00 per share, with a total value of $499,996.00. Following the transaction, the director owned 196,428 shares of the company’s stock, valued at $1,374,996. The trade was a 57.14% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Aaron G.L. Fletcher acquired 71,428 shares of the business’s stock in a transaction that occurred on Friday, June 27th. The stock was bought at an average cost of $7.00 per share, for a total transaction of $499,996.00. Following the completion of the transaction, the director directly owned 196,428 shares in the company, valued at $1,374,996. This represents a 57.14% increase in their position. The disclosure for this purchase can be found here. Insiders bought 214,284 shares of company stock valued at $1,499,988 in the last quarter. Company insiders own 69.34% of the company’s stock.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.